

# Safi Shahda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10887304/publications.pdf>

Version: 2024-02-01

31  
papers

1,141  
citations

394421

19  
h-index

454955

30  
g-index

31  
all docs

31  
docs citations

31  
times ranked

2348  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review. American Journal of Gastroenterology, 2017, 112, 537-554.	0.4	123
2	Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 673-684.	7.3	98
3	Regulation of HIF1 $\alpha$ under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models. Molecular Cancer Therapeutics, 2016, 15, 2722-2732.	4.1	91
4	APE1/Ref-1 Regulates STAT3 Transcriptional Activity and APE1/Ref-1 $\alpha$ -STAT3 Dual-Targeting Effectively Inhibits Pancreatic Cancer Cell Survival. PLoS ONE, 2012, 7, e47462.	2.5	84
5	Phase 1 study of EUS-guided photodynamic therapy for locally advanced pancreatic cancer. Gastrointestinal Endoscopy, 2019, 89, 390-398.	1.0	68
6	Family caregiving challenges in advanced colorectal cancer: patient and caregiver perspectives. Supportive Care in Cancer, 2016, 24, 2017-2024.	2.2	61
7	Positive changes among patients with advanced colorectal cancer and their family caregivers: a qualitative analysis. Psychology and Health, 2017, 32, 94-109.	2.2	61
8	Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. Clinical Cancer Research, 2018, 24, 6204-6211.	7.0	61
9	A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Investigational New Drugs, 2020, 38, 821-830.	2.6	59
10	A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer.. Journal of Clinical Oncology, 2017, 35, 3541-3541.	1.6	53
11	The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 1083-1101.	7.3	46
12	A systematic review of psychosocial interventions for colorectal cancer patients. Supportive Care in Cancer, 2017, 25, 2349-2362.	2.2	35
13	A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors. Oncologist, 2019, 24, 14-e10.	3.7	32
14	Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study. BMC Cancer, 2019, 19, 468.	2.6	31
15	Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 2146-2161.	7.3	31
16	Examining the effect of peer helping in a coping skills intervention: a randomized controlled trial for advanced gastrointestinal cancer patients and their family caregivers. Quality of Life Research, 2018, 27, 515-528.	3.1	29
17	Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 5348-5357.	7.0	29
18	Identification of Potential Serum Protein Biomarkers and Pathways for Pancreatic Cancer Cachexia Using an Aptamer-Based Discovery Platform. Cancers, 2020, 12, 3787.	3.7	27

#	ARTICLE	IF	CITATIONS
19	Phase 1 Pharmacogenetic and Pharmacodynamic Study of Sorafenib With Concurrent Radiation Therapy and Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 284-291.	0.8	25
20	Social correlates of mental health in gastrointestinal cancer patients and their family caregivers: Exploring the role of loneliness. <i>Supportive Care in Cancer</i> , 2019, 27, 2077-2086.	2.2	15
21	Homologous Recombination Deficiency in Patients With Pancreatic Ductal Adenocarcinoma and Response to Chemotherapy. <i>JCO Precision Oncology</i> , 2018, 2, 1-11.	3.0	13
22	Simultaneous Inhibition of MEK and Hh Signaling Reduces Pancreatic Cancer Metastasis. <i>Cancers</i> , 2018, 10, 403.	3.7	13
23	Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2017, 37, 5533-5539.		13
24	Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2016, 21, 664-665d.	3.7	11
25	Profiling of Adipose and Skeletal Muscle in Human Pancreatic Cancer Cachexia Reveals Distinct Gene Profiles with Convergent Pathways. <i>Cancers</i> , 2021, 13, 1975.	3.7	9
26	Myeloid sarcoma of the sigmoid colon: An unusual presentation of a rare condition. <i>Digestive and Liver Disease</i> , 2017, 49, 1280.	0.9	5
27	Regorafenib: from bench to bedside in colorectal cancer. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 243-248.	3.1	4
28	GI-4000 in KRAS mutant cancers. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 273-278.	4.1	4
29	A phase 1b/2 study of INCB039110 + nab-paclitaxel (N) and gemcitabine (G) in patients (pts) with advanced solid tumors and pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 362-362.	1.6	4
30	Two Months of Therapy: A Case of Pathologic Complete Response to Chemoimmunotherapy in a Patient With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e229-e232.	2.3	3
31	A phase 1b dose escalation study of vintictumab (VAN) in combination with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients with previously untreated stage IV pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 249-249.	1.6	3